These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 12637475)

  • 1. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma.
    Cheung IY; Lo Piccolo MS; Kushner BH; Kramer K; Cheung NK
    J Clin Oncol; 2003 Mar; 21(6):1087-93. PubMed ID: 12637475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8.
    Cheung IY; Lo Piccolo MS; Collins N; Kushner BH; Cheung NK
    Cancer; 2002 Jun; 94(11):3042-8. PubMed ID: 12115395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma.
    Cheung IY; Lo Piccolo MS; Kushner BH; Cheung NK
    J Clin Oncol; 2003 Oct; 21(20):3853-8. PubMed ID: 14551304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR.
    Cheung IY; Cheung NK
    Clin Cancer Res; 2001 Jun; 7(6):1698-705. PubMed ID: 11410509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age.
    Cheung NK; Kushner BH; Cheung IY; Kramer K; Canete A; Gerald W; Bonilla MA; Finn R; Yeh SJ; Larson SM
    J Clin Oncol; 1998 Sep; 16(9):3053-60. PubMed ID: 9738575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
    Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ
    Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.
    Cheung NK; Ostrovnaya I; Kuk D; Cheung IY
    J Clin Oncol; 2015 Mar; 33(7):755-63. PubMed ID: 25559819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.
    Cheung NK; Cheung IY; Kushner BH; Ostrovnaya I; Chamberlain E; Kramer K; Modak S
    J Clin Oncol; 2012 Sep; 30(26):3264-70. PubMed ID: 22869886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.
    Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
    Med Pediatr Oncol; 2001 Jan; 36(1):194-6. PubMed ID: 11464881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma.
    Cheung NK; Cheung IY; Kramer K; Modak S; Kuk D; Pandit-Taskar N; Chamberlain E; Ostrovnaya I; Kushner BH
    Int J Cancer; 2014 Nov; 135(9):2199-205. PubMed ID: 24644014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).
    Mora J; Cruz O; Lavarino C; Rios J; Vancells M; Parareda A; Salvador H; Suñol M; Carrasco R; Guillen A; Mañé S; de Torres C
    Clin Transl Oncol; 2015 Jul; 17(7):521-9. PubMed ID: 25596034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GD2 synthase: a new molecular marker for detecting neuroblastoma.
    Lo Piccolo MS; Cheung NK; Cheung IY
    Cancer; 2001 Aug; 92(4):924-31. PubMed ID: 11550167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
    Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
    Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G
    Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Kramer K; Modak S; Yataghene K; Cheung NK
    Oncoimmunology; 2015 Jul; 4(7):e1016704. PubMed ID: 26140243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma.
    Cheung IY; Vickers A; Cheung NK
    Int J Cancer; 2006 Jul; 119(1):152-6. PubMed ID: 16450393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor.
    Cheung NK; Sowers R; Vickers AJ; Cheung IY; Kushner BH; Gorlick R
    J Clin Oncol; 2006 Jun; 24(18):2885-90. PubMed ID: 16682723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow.
    Hoon DS; Kuo CT; Wen S; Wang H; Metelitsa L; Reynolds CP; Seeger RC
    Am J Pathol; 2001 Aug; 159(2):493-500. PubMed ID: 11485908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis.
    Cheung IY; Sahota A; Cheung NK
    Cancer; 2004 Nov; 101(10):2303-8. PubMed ID: 15484213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
    Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
    Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma.
    Cheung NK; Guo HF; Heller G; Cheung IY
    Clin Cancer Res; 2000 Jul; 6(7):2653-60. PubMed ID: 10914706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.